Literature DB >> 6110975

Genetically determined impaired drug sulphoxidation.

R H Waring, S C Mitchell, J R Idle, R L Smith.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 6110975     DOI： 10.1016/s0140-6736(81)92647-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

Authors:  P Dayer; L Balant; A Küpfer; F Courvoisier; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 2.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

3.  Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.

Authors:  S C Mitchell; R H Waring; C S Haley; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

4.  An investigation of the metabolism of S-carboxymethyl-L-cysteine in man using a novel HPLC-ECD method.

Authors:  E F Karim; J S Millership; D J Temple; A D Woolfson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

5.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

6.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.